FDA to Hear Appeal on Breast Cancer Drug06/28/11
TUESDAY, June 28 (HealthDay News) -- The controversial cancer
drug Avastin becomes the focus of U.S. regulators' attention again
Tuesday during a two-day hearing to determine if the medication can
keep its FDA approval for the treatment of metastatic breast
Back on Dec. 16, the U.S. Food and Drug Administration
recommended revoking approval of the drug to fight breast cancer,
citing the medication's poor performance in follow-up studies and
its potential for serious side effects.
The drug's maker, Genentech, now owned by the pharmaceutical
giant Roche, was given the chance to appeal the FDA recommendation
and present additional evidence. That appeal will be the focus of
the hearing and, according to published reports, will involve
Genentech urging one more clinical trial before any government
action on the drug.
The FDA's unusual step of scheduling another hearing on the drug
underscores the difficulty of withdrawing approval of a cancer
Associated Press reported.
"It says to me that either they [the FDA] have gotten a great deal of negative feedback from various quarters, or there's some kind of internal disagreement within the agency," Dr. Gary Lyman, professor at the Duke Cancer Institute in North Carolina, told the news service. Lyman was part of the FDA advisory panel that voted 12-1 last July to revoke Avastin's approval as a breast cancer therapy.
The FDA's December recommendation did not immediately affect
breast cancer patients' access to the drug or limit use of Avastin
(bevacizumab) for advanced colon, lung, kidney and brain
"FDA has taken the first step to removing the breast cancer indication from the label of the cancer drug Avastin," Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, announced at the Dec. 16 news conference. "This is a first step in a process and will not have an immediate impact on use of Avastin or the drug's availability."
"Oncologists currently treating patients with Avastin should use medical judgment in deciding whether to continue treatment or explore other treatment options," she added.
Some doctors expressed concern at the FDA's decision last
"This is a tough issue. There are women who have clearly responded to the treatment, [and] this is going to be a very difficult pill to swallow for those women," said Dr. Neil Spector, professor of medicine at the Duke Cancer Institute.
"There's a very real possibility that there may be a subgroup of women that are likely to respond to this," Spector said. "I don't think this will be the end from the standpoint of investigation and people trying to understand who that subpopulation is. It's just unfortunate that this will put a huge crimp in trying to figure that out."
Another expert, Dr. Julie Gralow, director of breast medical
oncology at the Seattle Cancer Care Alliance (SCCA), called the FDA
"It is clear that some breast cancer patients derive substantial benefit from Avastin," Gralow, who is also professor in the Medical Oncology Division of the University of Washington School of Medicine, said in a SCAA press statement. "We don't know how to select those tumors or patients yet. It is looking like patient factors, not tumor factors, might be the best way to select those who benefit. To withhold this drug from all patients because some don't benefit is incorrect."
Doctors can continue to prescribe Avastin to patients
"off-label," as they do other drugs. But it's unlikely that
insurance companies would cover off-label use of the drug given its
high price tag, Spector said. Avastin costs more than $8,000 a
month, according to published reports.
The FDA last December did not rule out the possibility that if
Avastin is actually revoked, approval could be restored for certain
subgroups of patients who may benefit.
"FDA is ready to work with Genentech on any proposals to conduct additional studies in metastatic breast cancer designed to identify responsive tumors," Woodcock added at the time.
Avastin was OK'd in 2008 for use in conjunction with
chemotherapy under the FDA's accelerated approval program. Approval
was based on one clinical trial of patients with metastatic
HER2-negative breast cancer that found a benefit in terms of cancer
recurrence -- but not overall survival -- and was contingent on
further data to confirm the results.
Three subsequent studies failed to find an overall survival
benefit and, in fact, showed less impressive improvements in
survival involving no progression of cancer.
After reviewing all four studies, FDA concluded that "patients
receiving Avastin did not live any longer than patients not treated
with the drug and were at greater risk of severe side effects, some
of which are unique to Avastin," Woodcock said.
"These include perforations of the nose, stomach and intestine, many of which can be life-threatening, as well as high blood pressure, heart attack or heart failure, wound-healing complications and organ damage or failure," she said.
The U.S. National Cancer Institute has more on
Copyright © 2010
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.